Numab Therapeutics AG announced today the first patient has been dosed in its proprietary ND021 program, a next-generation tri-specific immuno-oncology approach targeting PD-L1, 4-1BB and Serum Albumin. The study will initially enroll up to 102 cancer patients at four major clinical sites across the United States and Taiwan and will expand to additional centers as the study progresses. In its first part, this international, multi-center Phase 1/2 clinical study will investigate the safety and tolerability of ascending doses of NM21-1480, the company’s clinical lead molecule in the ND021 program, in patients with various forms of solid tumors and establish a recommended dose for continued clinical development. The trial will subsequently explore the anti-tumor activity of the compound in patients suffering from selected tumor types.  

Numab Therapeutics and Boehringer Ingelheim today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life-changing breakthrough therapies with Numab’s multi-specific antibody platform.   Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell-directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases, Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next-generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.

Numab announced today an expansion of its relationship with Ono Pharmaceutical Co., Ltd. by executing another research and option agreement to discover and develop a multi-specific antibody drug candidate for the treatment of various cancers. Similar to their earlier collaboration initiated in March 2017, under this new agreement, Ono has obtained an option to acquire from Numab exclusive rights to develop and commercialize an immuno-oncology drug candidate that will leverage Numab’s platform technology in order to actualize one of Ono’s novel therapeutic approaches. In exchange, Ono will pay to Numab up to CHF 260 million in upfront and milestone payments plus tiered single to double-digit royalties on sales.

Numab Therapeutics AG announced today the closing of its Series B financing round at a total volume of CHF 22M (approximately USD 22.6M). New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella. Existing shareholders that participated in Numab’s Series A round also contributed to today’s financing. With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic. The company also plans to initiate a clinical trial for its lead oncology program ND021 during the course of 2020.

Numab Therapeutics AG today announced a partnership with 3SBio’s subsidiary Sunshine Guojian Pharmaceutical focusing on the development and commercialization of a portfolio of novel multi-specific cancer antibodies. As part of the alliance, Sunshine Guojian has invested CHF15M (approximately USD 15.2M) in Numab’s series B financing.

Wädenswil, Switzerland, October 15, 2019 – Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr. Daniel Vasella to its Board of Directors.

ZURICH, SWITZERLAND, October 1, 2019 – Numab Therapeutics AG (Numab) today announced the initiation of a partnership with Eisai, Co., Ltd (Eisai), under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform.

Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals (HKEX: 2616) and Numab Therapeutics AG today announce that they have entered into an exclusive regional licensing agreement for the development and commercialization of ND021, a potential best-in-class monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin (HSA).

Numab delivered a poster presentation today, providing new animal data on its lead I/O drug candidate, NM21-1480, emerging from the company’s ND021 program. NM21-1480 is a PD-L1/4-1BB/HSA trispecific scMATCH3 that simultaneously blocks PD-(L)1 signaling and conditionally costimulates 4-1BB+ cells in the tumor microenvironment. The unique properties of NM21-1480 enables best-in-class antitumoral efficacy while avoiding extratumoral activity and thereby preventing any 4-1BB-mediated toxicities. Studies in mice and non-human primates support NM21-1480 as a safe and highly effective drug candidate for a variety of cancers. Please click here to view the poster.

Pfäffikon, Switzerland, March 5, 2019 – Numab Therapeutics AG today announced that Intarcia Therapeutics Inc. has executed its option to in-license ND016, being developed for the treatment of autoimmune disorders. Numab discovered ND016 on behalf of Intarcia under a previous research and option agreement. Under the present exclusive license agreement, Intarcia receives worldwide rights to develop and commercialize ND016 in exchange for license payments of up to CHF 70 million and up to double digit tiered royalties on net sales.

Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced the appointments of Prof. Mario Sznol from Yale Cancer Center and Prof. David Hong from the MD Anderson Cancer Center to its clinical advisory board. They will join Dr. Ignacio Melero who was appointed in September last.

Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. Ignacio Javier Melero Bermejo as scientific advisor. Ignacio Melero, M.D., Ph.D., is professor of immunology at the Academic Hospital of Navarra and at the Center for Applied Medical Research (CIMA) of the University of Navarra. He leads a group working in translational tumor immunotherapy with emphasis on cell therapy, cytokine gene therapy, and immune-stimulatory monoclonal antibodies.

Numab Therapeutics AG today presents preclinical efficacy data for its immuno-oncology lead product ND021 at the Annual Meeting of the American Association for Cancer Research (AACR). ND021 is a trispecific molecule that simultaneously targets PDL1 on cancer and a costimulatory receptor on T cells. The preclinical data presented today confirm the differentiating potential of ND021 in terms of efficacy and safety over PD-1/PDL1 blocking agents and their combination with antibodies targeting the costimulatory receptor. Please click on the link below to download the AACR poster presentation.

Intarcia Therapeutics, Inc., and Numab Therapeutics AG today announced the achievement of a key milestone in their on-going development partnership – the selection of a multi-specific antibody construct targeting autoimmune and inflammatory diseases. This delivery marks the first major milestone in the strategic relationship, established in the spring of 2015, and triggers a payment to Numab that will bring the total payments for this project to CHF 11.5 million to date.  

Numab Therapeutics AG ("Numab") today announced a collaboration and option agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the identification of a multispecific antibody candidate for development in inflammatory disease. Under the agreement, Kaken will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its unique multispecific antibody technology platform. Kaken is to fully fund the research program.

Numab Therapeutics AG (“Numab”) today announced a research and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”) for the identification of a multi-specific antibody candidate for development in immunooncology.

Intarcia Therapeutics, Inc., and Numab AG, today announced the achievement of several key milestones in the development of a multi-specific antibody targeting inflammatory / autoimmune diseases. This is an important step towards realizing the potential of combining Numab’s antibody- based therapeutics with Intarcia’s unique delivery and formulation technologies. Read more in the PDF below.

Tillotts Pharma AG (“Tillotts”) and Numab AG announced today that they have entered into an exclusive global licensing agreement to develop and commercialize new antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD). The partnership demonstrates Tillotts’ commitment to developing new treatments to improve care for patients with IBD and, upon successful development, will add to a strong track record in the registration and marketing of IBD treatments globally. Read more in the PDF below.

Intarcia Therapeutics, Inc. and Numab AG today announced a strategic collaboration focused on the development of once- or twice-yearly mono-specific and multi-specific antibodies addressing diabetes, obesity and autoimmune indications. Read more in the PDF below.